The Scott & White Heart & Vascular Institute in Temple, Texas, has earned The Joint Commission's Gold Seal of Approval as a hospital performing ventricular assist device as a destination therapy, according to a news release.
Destination therapy is permanent support for end-stage heart failure by means of an implantable artificial heart device.
Scott & White underwent an on-site survey by a team of Joint Commission surveyors who evaluated Scott & White's Heart & Vascular Institute's VAD program for compliance with standards of care specific to the needs of patients and families, including infection prevention and control, leadership and medication management. The approval means the program demonstrated compliance with The Joint Commission's national standards for healthcare quality and safety in disease-specific care.
Destination therapy is permanent support for end-stage heart failure by means of an implantable artificial heart device.
Scott & White underwent an on-site survey by a team of Joint Commission surveyors who evaluated Scott & White's Heart & Vascular Institute's VAD program for compliance with standards of care specific to the needs of patients and families, including infection prevention and control, leadership and medication management. The approval means the program demonstrated compliance with The Joint Commission's national standards for healthcare quality and safety in disease-specific care.
Related Articles on The Joint Commission:
Joint Commission Launches 'Targeted Solutions Tool' for Wrong-Site Surgery
Joint Commission Publishes 2012 National Patient Safety Goals Slide Presentation
Joint Commission Set to Launch Tool for Wrong-Site Surgery